Palvella Therapeutics (NASDAQ:PVLA) Stock Price Expected to Rise, Chardan Capital Analyst Says

Palvella Therapeutics (NASDAQ:PVLA) had its target price raised by Chardan Capital from $60.00 to $73.00 in a research report report published on Friday,Benzinga reports. Chardan Capital currently has a buy rating on the stock.

Other analysts have also recently issued reports about the company. Truist Financial began coverage on Palvella Therapeutics in a research note on Monday, July 21st. They issued a “buy” rating and a $56.00 price target on the stock. Lifesci Capital assumed coverage on Palvella Therapeutics in a report on Monday, August 4th. They issued an “outperform” rating and a $90.00 price objective on the stock. Raymond James Financial set a $54.00 target price on Palvella Therapeutics and gave the stock an “outperform” rating in a research note on Tuesday, August 5th. Canaccord Genuity Group upped their price target on Palvella Therapeutics from $52.00 to $66.00 and gave the company a “buy” rating in a report on Tuesday, August 19th. Finally, HC Wainwright raised their price objective on shares of Palvella Therapeutics from $75.00 to $95.00 and gave the stock a “buy” rating in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating and eleven have issued a Buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $67.09.

Palvella Therapeutics Stock Up 3.3%

NASDAQ PVLA opened at $59.59 on Friday. Palvella Therapeutics has a 52 week low of $11.17 and a 52 week high of $63.12. The stock has a market capitalization of $659.07 million, a PE ratio of -4.92 and a beta of -0.04. The firm has a 50 day moving average of $48.78 and a two-hundred day moving average of $32.91.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.08). On average, equities research analysts expect that Palvella Therapeutics will post -3.69 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC purchased a new stake in Palvella Therapeutics in the first quarter valued at approximately $7,553,000. Woodline Partners LP acquired a new position in shares of Palvella Therapeutics in the 1st quarter valued at $5,435,000. Clio Asset Management LLC purchased a new stake in Palvella Therapeutics in the 2nd quarter valued at $2,063,000. Geode Capital Management LLC boosted its stake in Palvella Therapeutics by 84.7% during the 2nd quarter. Geode Capital Management LLC now owns 173,986 shares of the company’s stock worth $3,923,000 after purchasing an additional 79,787 shares during the period. Finally, Royce & Associates LP purchased a new position in Palvella Therapeutics during the 1st quarter worth $2,002,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.